Please assess the completion status of the following clinical trial:

Trial Title: Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent given by patients and/or patient's parent(s) or legal acceptable representative(s) (guardian(s)) according to national regulations~2. Type 1 Diabetes (T1D) according to the Amercian Diabetes Association (ADA) classification diagnosed ≤6 months at the time of screening~3. Age: ≥12 and \<25 years old~4. Fasting C-peptide ≥0.12 nmol/L (0.36 ng/ml) on at least one occasion (maximum 2 tests on different days within a period of 2 weeks)~5. Positive for Glutamic Acid Decarboxylase isoform 65 (GAD65A) but \< 50 000 IU/ml~6. Females must agree to avoid pregnancy and have a negative urine pregnancy test. Patients of childbearing potential must agree to use adequate contraception, until one (1) year after the last administration of Diamyd. Adequate contraception is as follows:~For females of childbearing potential:~1. oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or implanted hormonal contraceptives~2. combined (estrogen and progestogen containing)~3. oral, intravaginal or transdermal progesterone hormonal contraception associated with inhibition of ovulation~4. intrauterine device~5. intrauterine hormone-releasing system (for example, progestin-releasing coil)~6. bilateral tubal occlusion~7. vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)~8. male partner using condom~9. abstinence from heterosexual intercourse~For males of childbearing potential:~1. condom (male)~2. abstinence from heterosexual intercourse~Exclusion Criteria:~1. Previous or current treatment with immunosuppressant therapy (although topical or inhaled steroids are accepted)~2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of headache or in connection with fever a few days will be accepted)~3. Treatment with any oral or injected anti-diabetic medications other than insulin~4. A history of anemia or significantly abnormal hematology results at screening~5. A history of epilepsy, head trauma or cerebrovascular accident, or clinical features of continuous motor unit activity in proximal muscles~6. Clinically significant history of acute reaction to vaccines or other drugs in the past~7. Treatment with any vaccine, including influenza vaccine, within 4 months prior to planned first study drug dose or planned treatment with any vaccine up to 4 months after the last injection with study drug.~8. Participation in other clinical trials with a new chemical entity within the previous 3 months~9. Inability or unwillingness to comply with the provisions of this protocol~10. A history of alcohol or drug abuse~11. A significant illness other than diabetes within 2 weeks prior to first dosing~12. Known HIV or hepatitis~13. Females who are lactating or pregnant (the possibility of pregnancy must be excluded by urine βHCG on-site within 24 hours prior to the Diamyd/placebo treatment)~14. Presence of associated serious disease or condition, including active skin infections that preclude intralymphatic injection, which in the opinion of the investigator makes the patient non-eligible for the study~15. Deemed by the investigator not being able to follow instructions and/or follow the study protocol

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Active arm (Type: ACTIVE_COMPARATOR): Patients will be assigned to receive i) three (3) intralymphatic injections with Recombinant human Glutamic Acid Decarboxylase adsorbed to Alhydrogel (Diamyd) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
- Placebo arm (Type: PLACEBO_COMPARATOR): Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)

Based on this trial design, predict the completion outcome and termination type (if applicable).